| SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor M Hoffmann, H Kleine-Weber, S Schroeder, N Krüger, T Herrler, ... cell 181 (2), 271-280. e8, 2020 | 22560 | 2020 |
| A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells M Hoffmann, H Kleine-Weber, S Pöhlmann Molecular cell 78 (4), 779-784. e5, 2020 | 2045 | 2020 |
| SARS-CoV-2 variants B. 1.351 and P. 1 escape from neutralizing antibodies M Hoffmann, P Arora, R Groß, A Seidel, BF Hörnich, AS Hahn, N Krüger, ... Cell 184 (9), 2384-2393. e12, 2021 | 1008 | 2021 |
| The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic M Hoffmann, N Krüger, S Schulz, A Cossmann, C Rocha, A Kempf, ... Cell 185 (3), 447-456. e11, 2022 | 921 | 2022 |
| The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells M Hoffmann, H Kleine-Weber, N Krüger, M Müller, C Drosten, ... BioRxiv, 2020.01. 31.929042, 2020 | 891 | 2020 |
| Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies D Wrapp, D De Vlieger, KS Corbett, GM Torres, N Wang, W Van Breedam, ... Cell 181 (5), 1004-1015. e15, 2020 | 682 | 2020 |
| Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19 M Hoffmann, S Schroeder, H Kleine-Weber, MA Müller, C Drosten, ... Antimicrobial agents and chemotherapy 64 (6), 10.1128/aac. 00754-20, 2020 | 524 | 2020 |
| Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2 M Hoffmann, K Mösbauer, H Hofmann-Winkler, A Kaul, H Kleine-Weber, ... Nature 585 (7826), 588-590, 2020 | 476 | 2020 |
| Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination J Barros-Martins, SI Hammerschmidt, A Cossmann, I Odak, MV Stankov, ... Nature medicine 27 (9), 1525-1529, 2021 | 440 | 2021 |
| Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity M Hoffmann, H Hofmann-Winkler, JC Smith, N Krüger, P Arora, ... EBioMedicine 65, 2021 | 351 | 2021 |
| SARS-CoV-2 variant B. 1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination M Hoffmann, H Hofmann-Winkler, N Krüger, A Kempf, I Nehlmeier, ... Cell reports 36 (3), 2021 | 273 | 2021 |
| LY6E impairs coronavirus fusion and confers immune control of viral disease S Pfaender, KB Mar, E Michailidis, A Kratzel, IN Boys, P V’kovski, W Fan, ... Nature microbiology 5 (11), 1330-1339, 2020 | 218 | 2020 |
| Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization D Lapuente, J Fuchs, J Willar, A Vieira Antão, V Eberlein, N Uhlig, ... Nature communications 12 (1), 6871, 2021 | 194 | 2021 |
| Pharmacological inhibition of acid sphingomyelinase prevents uptake of SARS-CoV-2 by epithelial cells A Carpinteiro, MJ Edwards, M Hoffmann, G Kochs, B Gripp, S Weigang, ... Cell Reports Medicine 1 (8), 2020 | 193 | 2020 |
| Functional analysis of potential cleavage sites in the MERS-coronavirus spike protein H Kleine-Weber, MT Elzayat, M Hoffmann, S Pöhlmann Scientific reports 8 (1), 16597, 2018 | 178 | 2018 |
| Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants R Groß, M Zanoni, A Seidel, C Conzelmann, A Gilg, D Krnavek, ... EBioMedicine 75, 2022 | 159 | 2022 |
| Mutations in the spike protein of Middle East respiratory syndrome coronavirus transmitted in Korea increase resistance to antibody-mediated neutralization H Kleine-Weber, MT Elzayat, L Wang, BS Graham, MA Müller, C Drosten, ... Journal of virology 93 (2), 10.1128/jvi. 01381-18, 2019 | 144 | 2019 |
| Omicron sublineage BQ. 1.1 resistance to monoclonal antibodies P Arora, A Kempf, I Nehlmeier, SR Schulz, HM Jäck, S Pöhlmann, ... The Lancet Infectious Diseases 23 (1), 22-23, 2023 | 140 | 2023 |
| SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants F Tea, A Ospina Stella, A Aggarwal, D Ross Darley, D Pilli, D Vitale, ... PLoS medicine 18 (7), e1003656, 2021 | 140 | 2021 |
| The SARS-CoV-2 and other human coronavirus spike proteins are fine-tuned towards temperature and proteases of the human airways M Laporte, V Raeymaekers, R Van Berwaer, J Vandeput, ... PLoS pathogens 17 (4), e1009500, 2021 | 135 | 2021 |
